Since its initiation in 2007, the CML Advocates Network has grown at an amazing pace. Since January 2015, 10 new organizations from 7 countries have joined the network! Our newest members are the "Indonesian CML & GIST Community (ELGEKA Indonesia)" and “Leucémie Espoir” from Mali. WELCOME! With this, we have now reached a total of 100 members based in 76 countries worldwide! See the list of CML groups in the Network on our world map.
The CML Clinical Trials Registry is growing steadily. Our database continues to benefit from additional studies which makes this resource increasingly valuable to patients. Seven new studies have been entered since November 2014. The registry now lists a total of 24 CML studies at http://www.cmladvocates.net/cmltrials and we are continually adding further studies as they become known to us. Thanks very much to everyone who provided information on new studies or helped ensure that the registry entries are correct and remain up to date.
The recently included studies are:
- a first-line trial with ponatinib for CML in accelerated phase;
- two trials after therapy failure or intolerance (early switch from imatinib to dasatinib (CA180-399), bosutinib after treatment with tyrosine kinase inhibitors (B1871039));
- a study comparing imatinib to nilotinib in CML in chronic phase;
- a study of decitabine plus dasatinib for CML in blast phase;
- a treatment discontinuation study (LAST); and
- eltrombopag for thrombocytopenia in CML.
For other studies that were previously included in the registry, we have updated the list of participating study centers and added study information or relevant links.
Recruitment has been completed in five studies, meaning that no further patients will be included. These studies have been moved to the new category “Trials that are no longer recruiting”.
The registry has also been improved by a new geographical feature. You can now find the region where the study is being performed in square brackets immediately behind the study title (for example, “Drug xy for CML in chronic phase [Europe, North America]).”
Do you know of any study that is not yet listed here? Please let us know by filling out this form.
Or is there an entry which should be corrected? If so, please send us an email.
Please also visit our discussion forum if you have any questions or wish to share your experience on these studies!
We are truly overwhelmed by the rapid growth of our network. Since January 2015, we have welcomed 8 new organizations from 5 countries! It´s so great to see the community growing at this pace! Today we want to welcome The National Cancer Control Foundation based in Yemen as our 98th member organisation. We now have members in 74 countries worldwide! See the list of CML groups in the Network on our world map.
Patient-friendly summary of the ELN CML Treatment Recommendations now also in Serbian - and 15 other languages
It is now available in 16 languages: English, Arabic, Bulgarian, Chinese (traditional and simplified), Dutch, French, German, Hebrew, Italian, Polish, Portuguese, Russian, Serbian, Spanish and Turkish (new: Serbian, thanks to Jelena from the CML Association of Serbia).
See our ELN Summary here: http://www.cmladvocates.net/cmlsummary
The CML Advocates Network is growing fast. We hereby proudly welcome four new members to our network. These are: APSBES / DILIGENCE GROUP from Togo, LUZ DE ESPERANZA from Peru, BCSG from Bangladesh and Zero Club from South Korea. With this we have now reached the number of 96 organisations from 72 countries across all continents. How exciting! See the list of CML groups in the Network on our world map.
The CML Advocates Network welcomes another new member: now 92 patient organisations from of 70 countries in the CML Advocates Network
We are delighted to welcome another new member to our network: the group "ASSOCIATION DE LUTTE CONTRE LES LEUCEMIES AU NIGER" is our first member organization based in Niger. WELCOME, NIGER! From today, the Network connects 92 organisations from 70 countries across all continents. See the list of CML groups in the Network on our world map.